WW International (WW), more commonly known as Weight Watchers, is fully embracing the popularity of GLP-1s and their impact ...

Weight Watchers, now known as WW International, has transitioned from a weight loss program to a health and wellness technology company. The company's financial health is concerning, with a market ...

A redesigned Weight Watchers experience pairs comprehensive GLP-1 support with personalized nutrition, coaching, community support, and cutting-edge technology to help members meet their weight loss ...

WW International stock has fallen by close to 8% over the last month and remains down by 77% year-to-date. It has been a perfect storm of sorts for the stock. The big health and fitness focus seen ...

Powerful healthcare company Eli Lilly introduced a new e-commerce platform that will surely boost sales of its new weight loss drug. Investors fear this will put a real dent in WW International's ...

Yesterday was a head-spinning day in the markets. After President Donald Trump announced out of the blue that he would be placing a 90-day pause on reciprocal tariffs for many countries—excluding ...

WW International stock (NASDAQ NDAQ: WW) has declined by close to 34% year-to-date to levels of around $10 per share. The stock has been on a weak footing for some time now, as the company’s digital ...

One stock that has been struggling out of the gate in 2024 is WW International (NASDAQ: WW), better known as WeightWatchers. Already down more than 50% this year, it has been in a rapid free fall and ...

Kingdom Capital Advisors, a private investment firm, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the third quarter, the portfolio recovered from ...

WW International (NASDAQ: WW) dropped by close to 25% in Wednesday’s trading, after the company published a weaker than expected set of Q2 2021 earnings and provided a tough outlook for the rest of ...

For a company to consistently earn economic profits, competitive advantages are necessary. WW will acquire Sequence, a telehealth platform focused on GLP-1 medications, and I doubt this deal will help ...